ADHD, the Menstrual Cycle, and Perimenopause: A Clinical Overview
- Jul 6
- 5 min read
When a client describes a symptom pattern that repeats — good weeks, then a reliably harder stretch before her period, or a steady worsening as she moves into perimenopause — the repetition is itself clinically useful. Estrogen-linked variation in ADHD is under-recognized, under-assessed, and, once named, often a relief to the client and a genuine aid to formulation.
The mechanism, and the evidence behind it
Estrogen modulates dopaminergic tone, and ADHD is characterized in part by altered dopamine neurotransmission. The mechanistic claim now has prospective support: in a 35-day daily-diary study of regularly cycling young women, within-person declines in estradiol — particularly alongside high progesterone or testosterone — predicted higher ADHD symptoms the following day, with effects strongest in women high in trait impulsivity [1]. The subsequent theory-and-evidence synthesis frames ADHD symptom risk as rising at points of rapid estrogen decline [2], and a 2025 systematic review locates the early luteal phase as the primary window of symptom worsening, with the early follicular phase secondary [5].
A precision note worth carrying to clients: several of these studies are small, and some of the supporting literature is qualitative. The convergence across prospective, review, and qualitative work is meaningful, but it is best presented as a well-supported pattern rather than settled quantitative fact.
Two timescales, one process
Clinically, the cycle and the transition are the same mechanism at different tempos. The menstrual cycle expresses estrogen withdrawal on a monthly loop, clustering symptom worsening in the early luteal and perimenstrual windows [5]. Perimenopause expresses it as erratic, then sustained, withdrawal — which maps onto the finding that women with ADHD report more severe perimenopausal symptoms, with earlier onset than women without ADHD [3]. STRAW+10 staging is useful for locating where a client sits on that arc and for anticipating when cycle-based strategies will need to give way to transition-specific ones. (See also the lifespan article for helpful diagrams)
PMDD comorbidity
Women with ADHD show elevated rates of hormone-related mood symptoms, including PMDD [6]. A recent 602-woman study quantifies the gap: PMDD in 40.3% of women with ADHD versus 6.2% without, and moderate-to-severe PMS in 46.3% versus 24.9%, alongside significantly higher menstrual irregularity [7]. Because PMDD is defined by prospective, phase-locked clustering in the late luteal phase, differentiating it from generalized cyclic worsening of ADHD requires prospective tracking across at least two cycles rather than retrospective report. Where PMDD is suspected, that is a referral and coordination point, not something to formulate around informally.
ADHD menstrual cycle: The late-diagnosis pathway
This is the throughline worth naming explicitly. The compensations that mask the monthly dip in adolescence and early adulthood often fail under the sustained withdrawal of perimenopause. When they do, the underlying ADHD becomes visible — which is why a substantial share of women are first identified in midlife, frequently after prior misattribution to anxiety or depression [4]. The field has begun naming the harms of late or incorrect diagnosis as a distinct priority [4]. For us, the clinical implication is twofold: a midlife presentation of "new" executive dysfunction warrants a developmental history rather than a purely current-state formulation, and the failure of long-standing coping is information about load and mechanism, not about effort or character.
The medication question — and the lane
A recurring clinical report, reflected in the literature, is diminished stimulant efficacy in low-estrogen phases, with preliminary evidence that premenstrual adjustment of psychostimulant dosage may ease inattention and mood difficulties [2][8]. This is worth surfacing — but the two-lane discipline matters here. Assessment, Medication timing and dosing belong to the prescriber. Our role is to notice and document the pattern, validate that it is real and not a matter of effort or compliance, and route the medication question appropriately. Naming the pattern without prescribing around it keeps us useful and in scope.
Continuing education
If you'd like to explore this further, I teach two CAMFT-approved CE courses on the intersection of trauma and hormonal transition:
Both are self-paced and CAMFT CE–approved (Provider #61115).
To learn more or enroll, visit Courses Page
About the Author
Julie Cardoza, MS, LMFT is a licensed marriage and family therapist and EMDRIA Approved Consultant specializing in Somatic EMDR, based in California. She is also an IWHI Certified Perimenopause/Menopause Health Coach and the founder of Heartscapes, LLC. She is a California C.E.P.A. #61115 offering self-paced training courses for therapists. Her work and writing is often at the intersection of trauma, neurobiology, and hormonal transitions, bringing a compassionate, body-based, and science-informed approach to healing. She is located in Central California, on the traditional homelands of the Yokuts and Mono peoples.
Disclaimer
The content on this blog is for educational and informational purposes only. It does not constitute therapy, medical advice, or establish a therapeutic relationship.
If you are experiencing a mental health crisis, please contact 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room. For professional support, consult with a licensed mental health provider in your area. If you are interested in EMDR therapy please visit emdria.org. Health information on the menopause transition is available at The Menopause Society at menopause.org.
You are responsible for how you use the information shared here. This content reflects my professional perspective and lived experience but is not a replacement for individualized care.
References
Roberts B, Eisenlohr-Moul T, Martel MM. Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology. 2018;88:105–114. https://doi.org/10.1016/j.psyneuen.2017.11.015
Eng AG, Nirjar U, Elkins AR, et al. Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidence. Hormones and Behavior. 2024;158:105466. https://doi.org/10.1016/j.yhbeh.2023.105466 · (PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC10872410/)
Perimenopausal symptoms in women with and without ADHD: A population-based cohort study. European Psychiatry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538516/
Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease (harms of late/incorrect diagnosis; midlife burden). Front Glob Womens Health. 2025. https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2025.1613628/full
Osianlis E, Thomas EHX, Jenkins LM, Gurvich C. ADHD and Sex Hormones in Females: A Systematic Review. Journal of Attention Disorders. 2025. https://journals.sagepub.com/doi/10.1177/10870547251332319
Dorani F, Bijlenga D, Beekman ATF, van Someren EJW, Kooij JJS. Prevalence of hormone-related mood disorder symptoms in women with ADHD. J Psychiatr Res. 2021;133:10–15. https://doi.org/10.1016/j.jpsychires.2020.12.005
Boyd C, Wrigley M, Kilbride K, Mulligan A, Bramham J. ADHD and the female reproductive stages: menstruation, perinatal and menopause. Archives of Women's Mental Health. 2026;29:89. https://doi.org/10.1007/s00737-026-01718-x
De Jong M, Wynchank DS, van Andel E, Beekman ATF, Kooij JJS. Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage. Frontiers in Psychiatry. 2023;14:1306194. https://doi.org/10.3389/fpsyt.2023.1306194
Supplementary narrative review (optional): Menstrual Cycle-Related Hormonal Fluctuations in ADHD: Effect on Cognitive Functioning — A Narrative Review. J Clin Med. 2025;15(1):121. https://www.mdpi.com/2077-0383/15/1/121
